- Pressemitteilung BoxID 151378
Geratherm Medical AG successfully completes capital increase
Capital stock raised by 10 percent / Strong demand among national and international investors
As part of the accelerated book building process, all 450,000 new shares being offered were successfully placed with qualified institutional investors both in Germany and abroad at EUR 8.00 per share. The capital increase therefore generated gross proceeds of around EUR 3.6 million.
By broadening the equity capital base, the shareholder structure was substantially expanded in Germany and abroad. With equity capital in excess of 80%, the Company believes that its strong balance sheet ratios put it in an excellent position to sustain its buoyant growth track from 2009. The inflow of funds is primarily intended to go towards further innovative product developments and also be invested in inorganic growth.
The Company's capital stock will be EUR 4,950,000.00 after the capital increase has been entered into the commercial register. The new shares are being released for trading in the regulated market (Prime Standard) of the Frankfurt Stock Exchange without prospectus.
The capital increase, which was considerably oversubscribed by national and international investors, was supported by Close Brothers Seydler Bank AG, Frankfurt am Main as sole lead manager und sole bookrunner.
Geratherm Medical AG
Geratherm Medical is an internationally operating medical products enterprise with the business areas 'Temperature Management', 'Cardio' and 'Respiratory'. Our company's roots are in temperature measurement in the medical sphere. In this business area we offer a broad spectrum of products, most of which have unique selling points. We supply our customers/patients with high-quality products ranging from thermometers to complex warming systems for use in the operating theatre and by emergency rescue services. In the Cardio business area we concentrate on the development of products for the detection of atrial fibrillation as a measure to prevent strokes. The Respiratory segment develops and markets products for the assessment of pulmonary function. In all three business areas, Geratherm has patent-protected basic technologies at its disposal. We regard ourselves as a research-based medical products company with a clear focus on medical diagnostic devices that generate vital data. Geratherm shares have been listed in the Prime Standard segment of the Frankfurt Stock Exchange since the year 2000. Geratherm Medical continues to be represented in the German Entrepreneurial Index and in the German Health-Care Index.
Diese Pressemitteilungen könnten Sie auch interessieren
Was können Opfer unerlaubter Bargeldabhebung durch Dritte tun? Scheck- und Kreditkarten sind grundsätzlich dadurch gekennzeichnet, dass sie...
Die Zahl der adoptierten Kinder und Jugendlichen ist im vergangenen Jahr erneut gestiegen. In 2016 haben nach Angaben des Statistischen Bundesamtes...
. - Umsätze im Q3 wachsen um 4,3% im Jahresvergleich auf EUR 123,3 Millionen - Normalisiertes EBITDA wächst um 7,2% auf EUR 68,3 Millionen gegenüber...